A Review of Experimental Design Best Practices for Proteomics Based Biomarker Discovery: Focus on SELDI-TOF

Protocol
First Online:
Part of the Methods in Molecular Biology book series (MIMB, volume 641)

Abstract

Surface Enhanced Laser/Desorption Ionization-time of flight (SELDI-TOF) mass spectrometry is a technique uniquely suited to the study of the urine proteome due to its salt tolerance, high-throughput, and small sample requirements. However, due to the extreme sensitivity of the technique, sample collection and storage conditions, as well as instrument protocols and analysis conditions, must be rigorously controlled to ensure that data generated and collected is accurate and free from artifacts. Robust and reproducible data sets can be generated and compared between clinical sites when experimental protocols are carefully standardized. This chapter aims to review known factors that cause irreproducible results so that the experiments may be designed with appropriate sample and process controls for successful biomarker discovery. A suggested protocol follows the review. A number of issues for study design are discussed and these are generally applicable to biomarker discovery experiments.

Key words

SELDI Proteomics Urine Mass spectrometry Methods Experimental design Protocol Protein profiling 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The author would like to thank Dr. Lee O. Lomas of Ciphergen Biosystems, Inc., for his invaluable insights, encouragement, and patience.

References

  1. 1.
    Bockenkamp, B. (2003) Understanding and managing acute fluid and electrolyte disturbances. Curr Paediatr 13(7), 520–528.CrossRefGoogle Scholar
  2. 2.
    Subcommittee on the Tenth Edition of the Recommended Dietary Allowances, Food and Nutrition Board, Commission on Life Sciences, National Research Council (1989) Recommended Dietary Allowances, 10th Edition. The National Academies Press, pp. 248–249.Google Scholar
  3. 3.
    Anderson, N.G., Anderson, N.L., Tollaksen, S.L., Hahn, H., Giere, F., and Edwards, J. (1979) Concentration and 2-D gel electrophoretic analysis of human urinary proteins. Anal Biochem 95, 48–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Kahn, A., and Packer, N.H. (2006) Simple urinary sample preparation for proteomic analysis. J Proteome Res 5, 2824–2838.CrossRefGoogle Scholar
  5. 5.
    Fung, E., Diamond, D., Simonsen, A.H., and Weinberger, S.R. (2003) The use of SELDI ProteinChip®® array technology in renal disease research. In: Renal Disease: Techniques and Protocols, (Goligorsky, M.S., ed.) Humana Press, Inc., Totowa, NJ, Chap. 20, p. 295.Google Scholar
  6. 6.
    Schaub, S., Wilkins, J., Weiler, T., Sangster, K., and Rush, D. (2004) Urine protein profiling with surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Kidney Int 65, 323–332.CrossRefPubMedGoogle Scholar
  7. 7.
    Khurana, M., Traum, A.Z., Aivado, M., Wells, M.P., Guerrero, F.G., Towia, A.L., and Schacter, A.D. (2006) Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol 21(9), 1257–1265.CrossRefPubMedGoogle Scholar
  8. 8.
    Nguyen, M.T., Ross, G.F., Dent, C.L., and Davarajan, P. (2005) Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 25, 318–326.CrossRefPubMedGoogle Scholar
  9. 9.
    Traum, A.Z., Wells, M.P., Aivado, M., Towia, A.L., Ramoni, M.F., and Schachter A.D. (2006) SELDI-TOF MS of quadruplicate urine and serum samples to evaluate changes related to storage conditions. Proteomics 6(5), 1676–1680.CrossRefPubMedGoogle Scholar
  10. 10.
    O’Riordan, E., Orlova, T.N., Mei, J.J., Butt, K., Chander, P.M., Rahman, S., Mya, M., Hu, R., Momin, J., Eng, E., Hampel, D.J., Hartman, B., Kretzler, M., Delaney, V., and Goligorsky, M.S. (2004) Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 15, 3240–3248.CrossRefPubMedGoogle Scholar
  11. 11.
    Petricoin, E.F., Ardekani, A.M., Hitt, B.A., Levine, P.J., Fusaro, V.A., Steinberg, S.M., Mills, G.B., Simone, C., Fishman, D.A., Kohn, E.C., and Liotta L.A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577.CrossRefPubMedGoogle Scholar
  12. 12.
    Baggerly, K.A., Morris, J.S., and Coombes, K.R. (2004) Reproducibility of SELDI-TOF protein patterns in serum: Comparing data sets from different experiments. Bioinformatics 20, 777–785.CrossRefPubMedGoogle Scholar
  13. 13.
    Baggerly, K.A., Coombes, K.R., and Morris, J.S. (2005) Bias, randomization, and ovarian proteomic data: A reply to “Producers and Consumers”. Cancer Inform 1(1), 1–7.Google Scholar
  14. 14.
    Liu, W., Guan, M., Wu, D., Zhang, Y., Wu, Z., Xu, M., and Lu, Y. (2005) Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur Urol 47, 456–462.CrossRefPubMedGoogle Scholar
  15. 15.
    Wolthers, O.D., Heuck, C., and Heickendorff, L. (2001) Diurnal variations in serum and urine markers of type I and type III collagen turnover in children. Clin Chem 47, 1721–1722.PubMedGoogle Scholar
  16. 16.
    Poon, T.C.W., Yip, T-T., Chan, A.T.C., Yip, C., Yip, V., Mok, T.S.K., Lee, C.Y., Leung, W.T., Ho, K.W., and Johnson, P.J. (2003) Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49, 752–760.CrossRefPubMedGoogle Scholar
  17. 17.
    Castagna, A., Cecconi, D., Sennels, L., Rappsilber, J., Guerrier, L., Fortis, F., Boschetti, E., Lomas, L., and Righetti, P.G. (2005) Exploring the hidden human urinary proteome via ligand library beads. J Proteome Res 4(6), 1917–1930.Google Scholar
  18. 18.
    Guerrier, L., Thulasiraman, V., Castagna, A., Fortis, F., Lin, S., Lomas, L., Righetti, P.G., and Boschetti, E. (2006) Reducing protein concentration range of biological samples using solid-phase ligand libraries. J Chromatogr B Analyt Technol Biomed Life Sci 833(1), 33–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Rai, A., Stemmer, P., Zhang, Z., Adam, B-L., Morgan, W., Caffrey, R., Podust, V., Patel, M., Semmes, J., Lim, L., Shipulina, N. (2005) Analysis of HUPO-PPP reference specimens using SELDI-TOF mass spectrometry: Multi-institution correlation of spectra and identification of biomarkers. Proteomics 5, 3467–3474.Google Scholar
  20. 20.
    Ganz, T. (2001) Defensins in the urinary tract and other tissues. J Infect Dis 183(Suppl. 1), S41–S42.Google Scholar
  21. 21.
    Kunin, C.M., Evans, C., Bartholomew, D., and Bates, D.G. (2002) The antimicrobial defense mechanism of the female urethra: A reassessment. J Urol 168, 413–419.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang, L., Yu, W., He, T., Yu, J., Caffrey, R.E., Dalmasso, E.A., Fu, S., Pham, T., Mei, J., Ho, J.J., Zhang, W., Lopez, P., Ho, D. (2003) Contribution of human alpha-defensin 1, 2 and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298, 995–1000.CrossRefGoogle Scholar
  23. 23.
    Hampel, D.J., Sonsome, C., Sha, M., Brodsky, S., Lawson, W.E., and Goligorsky, M.S. (2001) Towards proteomics in uroscopy: Urinary protein profiles after radiocontrast medium administration. J Am Soc Nephrol 12, 1026–1035.PubMedGoogle Scholar
  24. 24.
    Cazares, L.H., Adam, B.L., Ward, M.D., Nasim, S., Schellhammer, P.F., Semmes, O.J., and Wright, Jr, G.L. (2002) Normal, benign, pre-neoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface-enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res 8, 2541–2552.PubMedGoogle Scholar
  25. 25.
    Dr. Lee Lomas, Director of Research and Development, Ciphergen Biosystems, Inc., (2007) Personal communication.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.RichmondUSA

Personalised recommendations